Call Us

ARTICLES

Arthrosamid®’s story started two decades ago. The brainchild of the team at Contura, the product had been in human use for various indications since 2000, and a favourable safety profile had already been established.

Simplifying Safety: Who Should Avoid Sinogel & Chondroitin and Essential Aftercare Protocols

Introduction

When it comes to treating joint problems, safety should always come first. This article is designed to help both patients and healthcare professionals make the safest choices when considering Sinogel and Chondroitin. We’ll clearly explain who should steer clear of these treatments and share straightforward aftercare tips to support the best possible results. Our guidelines are grounded in reputable research, so you can feel confident putting them into practice.

Who Should Avoid Sinogel and Chondroitin?

Sinogel and Chondroitin aren’t suitable for everyone. If you have an active infection at or near the area needing treatment, you should avoid these products—using them could make the infection worse. People with joint effusion (when excess fluid causes your joint to swell) should also not use these treatments, as they may increase discomfort or complications. Additionally, if you are pregnant or breastfeeding, it’s important to avoid these treatments since we don’t have enough evidence to know that they’re safe during these times. These recommendations are based on clinical studies that highlight possible risks and the importance of cautious patient selection. Selecting the right candidates and timing for treatment is key in achieving safe outcomes and preventing complications.

Simple Aftercare Steps to Follow

Taking care of yourself after treatment is just as important as the procedure itself. After receiving your injection, keep an eye on the treated area. Watch for any redness, swelling, or unusual pain—these could be signs of an infection. If you notice the joint becoming more swollen or stiff, this could indicate fluid buildup and should be mentioned to your healthcare provider. Avoid strenuous activities or anything that puts extra pressure on the joint for at least a few days. Importantly, always stick to any specific instructions your healthcare provider gives you. These simple precautions can help you avoid complications and encourage a smooth recovery. Many studies show that following clear aftercare steps leads to safer, better outcomes.

Why These Safety Measures Matter

Understanding who should not receive Sinogel and Chondroitin—and following the right aftercare—protects your health and helps ensure a successful recovery. Careful patient selection, combined with dedicated aftercare, reduces the risk of side effects and encourages healing. Simple, clear safety guidelines not only keep patients safe but also increase the effectiveness of treatments overall. Research suggests that aftercare tailored to individual needs improves engagement and reduces complications, while structured aftercare has been shown to help people return to normal activities faster. With these tips, whether you’re a patient, caregiver, or health professional, you can approach joint treatment confidently and safely.

Conclusion

In summary, people with active infections, swollen joints caused by fluid, or those who are pregnant or breastfeeding should not use Sinogel or Chondroitin. After treatment, it’s important to watch for signs of infection, monitor for swelling, and avoid putting extra stress on your joint for a short time. By following these clear, research-backed steps, you maximize the benefits and safety of your treatment. With the right precautions, using Sinogel and Chondroitin for joint health can be both safe and effective.

References

Wand, A., Browne, R., Jessop, T., & Peisah, C. (2022). A systematic review of evidence-based aftercare for older adults following self-harm. Australian & New Zealand Journal of Psychiatry, 56(11), 1398-1420. https://doi.org/10.1177/00048674211067165

Nelson, K., & Nash, J. K. (2007). The effectiveness of aftercare services for African American families in an intensive family preservation program. Research on Social Work Practice, 18(3), 189-197. https://doi.org/10.1177/1049731508314263

Wilson, J. W. (1983). Treatment of auricular hematoma, using a teat tube. Journal of the American Veterinary Medical Association, 182(10), 1081-1083.

Navigating ICD-10 Nuances in Primary Osteoarthritis of the Left Knee: A Clinical and Research Perspective

This article explores the importance of accurate ICD-10 coding for primary osteoarthritis of the left knee, highlighting its role in precise diagnosis, treatment planning, and research. It discusses challenges in distinguishing primary from secondary osteoarthritis, the impact of coding errors on patient care and data integrity, and the need for ongoing clinician education. Accurate coding enhances treatment effectiveness, aids fall prevention, and supports the development of personalized therapies. Advances in imaging, patient-reported outcomes, and upcoming ICD-11 updates promise improved disease tracking and management, ultimately improving patient outcomes and healthcare efficiency.

Read More »

Targeted Relief for Meniscus-Deficient Knees: How Arthrosamid® Helps Ease Post-Meniscectomy Osteoarthritis Symptoms

Arthrosamid® is a novel single-injection polyacrylamide hydrogel designed to relieve post-meniscectomy osteoarthritis knee pain by cushioning and stabilizing the joint. Unlike traditional treatments providing temporary relief, Arthrosamid® integrates into the synovial membrane, reducing bone-on-bone contact and enhancing knee function. Clinical studies show significant pain reduction and improved mobility lasting up to two years, especially in patients under 70 with moderate OA and normal BMI. The treatment is minimally invasive, well-tolerated, and may delay or prevent the need for surgery. Arthrosamid® offers a promising alternative to hyaluronic acid injections with longer-lasting effects, marking a breakthrough in managing post-meniscectomy knee osteoarthritis.

Read More »